Results 211 to 220 of about 94,588 (272)

Intravitreal Bevacizumab for Diabetic Retinopathy

Current Diabetes Reviews, 2009
Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Macular edema within 1 disk diameter of the fovea is present in 9% of the diabetic population.
J Fernando, Arevalo, Rafael A, Garcia-Amaris   +1 more
openaire   +2 more sources

INTRAVITREAL BEVACIZUMAB DURING PREGNANCY

Retina, 2010
To report the clinical course of four women treated with intravitreal bevacizumab during pregnancy.Observational case series.Four pregnant women were treated with intravitreal bevacizumab for choroidal neovascularization (CNV) because of presumed ocular histoplasmosis syndrome punctate inner choroidopathy, or sarcoid uveitis.
Ryan M, Tarantola, James C, Folk, H Culver, Boldt, Vinit B, Mahajan   +3 more
openaire   +2 more sources

Intravitreal Bevacizumab for Diabetic Papillopathy

Journal of Ocular Pharmacology and Therapeutics, 2010
A 43-year-old woman presented with a visual acuity of 1/10 in the right eye and 3/10 in the left eye. Ophthalmologic examination disclosed optic disc swelling on both sides with mild nonproliferative diabetic retinopathy. The pupils were equal and reactive without an afferent pupillary defect.
Örnek, Kemal, Oğurel, Tevfik
openaire   +3 more sources

LARGE SILICONE DROPLETS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN)

Retinal cases & brief reports, 2017
Purpose: Despite its off-label status, intravitreal bevacizumab is the most commonly used intraocular anti–vascular endothelial growth factor agent. Regulation of compounding pharmacies has recently increased to make compounded pharmaceuticals safer ...
R. Avery, A. Castellarin, D. Dhoot, D. Pieramici, M. Nasir, N. Steinle, Logan P Avery, G. Gordon   +7 more
semanticscholar   +1 more source

Intravitreal Bevacizumab for Incontinentia Pigmenti

Journal of Pediatric Ophthalmology & Strabismus, 2013
Two eyes of two siblings affected with incontinentia pigmenti having severe proliferative retinopathy are reported. Both cases showed complete resolution of new vessels after a single injection of intravitreal bevacizumab. At 7 months of follow-up, the first case revealed vascularization to the mid-periphery including a vascularized fovea (
Parag K, Shah, Sandeep, Bachu, Venkatapathy, Narendran, Narendran, Kalpana, Jeevamala, David, Chakravarthi R, Srinivas   +5 more
openaire   +2 more sources

Intravitreal Anti-Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Utilization.

Ophthalmology (Rochester, Minn.), 2020
PURPOSE To model Medicare Part B and patient savings associated with increased bevacizumab payment and utilization for intravitreal anti-vascular endothelial growth factor (VEGF) therapy. DESIGN Cost analysis.
D. Glasser, R. Parikh, F. Lum, George A. Williams   +3 more
semanticscholar   +1 more source

Pharmacokinetics of Intravitreal Bevacizumab (Avastin)

Ophthalmology, 2007
To describe the pharmacokinetics of 1.25 mg of intravitreal bevacizumab (Avastin).Experimental animal study.Twenty Dutch-belted rabbits.One eye of each of 20 rabbits was injected with 1.25 mg of intravitreal bevacizumab. Both eyes of each of 4 rabbits were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in aqueous fluid,
Sophie J, Bakri, Melissa R, Snyder, Joel M, Reid, Jose S, Pulido, Ravinder J, Singh   +4 more
openaire   +2 more sources

Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization

American Journal of Ophthalmology, 2008
To assess the role of bevacizumab in inflammatory ocular neovascularization.Retrospective, multicenter, consecutive case series of inflammatory ocular neovascularization.Patients with inflammatory ocular neovascularization of varying causes for whom standard therapy failed were treated with intravitreal injection of bevacizumab.
Ahmad M, Mansour, Friederike, Mackensen, J Fernando, Arevalo, Focke, Ziemssen, Padmamalini, Mahendradas, Abla, Mehio-Sibai, Nicholas, Hrisomalos, Timothy Y Y, Lai, David, Dodwell, Wai-Man, Chan, Thomas, Ness, Alay S, Banker, Sivakami A, Pai, Maria H, Berrocal, Rania, Tohme, Arnd, Heiligenhaus, Ziad F, Bashshur, Moncef, Khairallah, Khalil M, Salem, Frank N, Hrisomalos, Matthew H, Wood, Wilson, Heriot, Alfredo, Adan, Atul, Kumar, Lyndell, Lim, Anthony, Hall, Matthias, Becker   +26 more
openaire   +3 more sources

Intravitreal Ranibizumab and Bevacizumab: A Review of Risk

Seminars in Ophthalmology, 2007
Ranibizumab (Lucentis), a recombinant monoclonal antibody, blocks all active forms of vascular endothelial growth factor A and was the first treatment for age-related macular degeneration shown to improve visual acuity in a substantial percentage of patients rather than slowing visual loss.
Rima M, Dafer, Michael, Schneck, Thomas R, Friberg, Walter M, Jay   +3 more
openaire   +2 more sources

Angioedema after intravitreal bevacizumab injection

Cutaneous and Ocular Toxicology, 2012
A 47-year-old male with a history of diabetes mellitus type 2 exhibited with decreased vision in both eyes. The diagnosis of cystoid macular edema (CME) was made and it was decided to administer bilateral intravitreal bevacizumab (Avastin) injections. After intravitreal bevacizumab injection (1.25 mg/0.05 cc) to the right eye the patient had angioedema
Yasin, Toklu, Ozge, Sarac, Sule, Berk, Saban, Simsek   +3 more
openaire   +2 more sources